[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Presented are our own results, along with literature data on dopamine receptors agonists, of Parkinson's disease (PD) therapy with mirapex. Thirty patients with PD (mean age 61,8 +/- 7,7 years, illness duration 8,4 +/- 1,3 years) were treated with mirapex in a mean dose 3,5 +/- 1,1 mg/day and levadopa. Mirapex efficacy was assessed with a number of quantitative scales. Mirapex improved patient's global state, movement and daily activity, and quality of life. The authors drew attention to the decrease of motor fluctuations expression and dyskinesias as well as anxiety, depression, cognitive dysfunction. The combination of high efficacy and good tolerability of mirapex is stressed.
Fedorova
N V
NV
Chigir'
I P
IP
D001007:Anxiety / Q000150:complications / Q000188:drug therapy; D052160:Benzothiazoles; D002230:Carbidopa / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003863:Depression / Q000150:complications / Q000188:drug therapy; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D000077487:Pramipexole; D017447:Receptors, Dopamine D1 / Q000819:agonists*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
D052160:Benzothiazoles; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists; D004338:Drug Combinations; D017447:Receptors, Dopamine D1; D013844:Thiazoles; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D000077487:Pramipexole; D002230:Carbidopa